Activation of spinal MrgC receptors inhibits hyperalgesia in rats.
- Author:
Jian-Ping JIANG
1
;
Yan FU
2
;
Fen-Juan HU
2
;
Yan-Guo HONG
2
Author Information
1. College of Life Sciences, Fujian Normal University, Fujian Key Laboratory of Developmental and Neuro Biology, Fuzhou 350117, China. jjp@fjnu.edu.cn.
2. College of Life Sciences, Fujian Normal University, Fujian Key Laboratory of Developmental and Neuro Biology, Fuzhou 350117, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Down-Regulation;
Freund's Adjuvant;
pharmacology;
Hyperalgesia;
drug therapy;
Inflammation;
metabolism;
Injections, Spinal;
Pain Measurement;
Peptide Fragments;
pharmacology;
Rats;
Receptors, G-Protein-Coupled;
metabolism;
Spinal Cord;
metabolism;
gamma-MSH;
pharmacology
- From:
Acta Physiologica Sinica
2015;67(4):413-422
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the mechanisms of the modulation effect of activation of spinal Mas-related gene C (MrgC) receptors on hyperalgesia induced by intraplantar (i.pl.) injection of (Tyr6)-γ2-MSH-6-12 (MSH) or complete Freund's adjuvant (CFA). Paw withdrawal latency test and immunohistochemistry were used to observe the effect of intrathecal (i.t.) administration of MSH or BAM8-22, two selective agonists of MrgC receptor, in hyperalgesia in rats. The results showed that i.t. administration of MSH inhibited acute hyperalgesic response induced by i.pl. application of MSH, while did not change thermal nociceptive threshold in naïve rats. The i.t. administration of MSH also attenuated CFA-induced inflammatory hyperalgesia. However, i.t. administration of the μ-opioid receptor (MOR) antagonist CTAP blocked the induction of delayed anti-hyperalgesia by MSH. The i.t. injection of BAM8-22 at a dose of 30 nmol evidently reduced the number of CFA-evoked nitric oxide synthase (NOS)-positive neurons and the expression of calcitonin gene-related peptide (CGRP)-immunoreactivity positive nerve fibers at L3-L5 segments of the spinal cord. These results suggest that the activation of MrgC receptor in CFA-induced inflammation reduces inflammatory hyperalgesia through inactivation of NOS neurons and down-regulation of CGRP expressions, and generates delayed but long-lasting anti-nociception through the endogenous activation of MOR via indirect mechanisms. Agonists for MrgC receptors may, therefore, represent a new class of antihyperalgesics for treating inflammatory pain because of the highly specific expression of their targets.
